Rheumatoid arthritis (RA) is a chronic,
progressive and incurable auto-immune disease that majorly affects the joints
in a human body. It is identified by synovial inflammation and gradual bone
erosion over the years. The major symptoms are stiffness, pain in hands and
feet and obstruct a patient’s mobility. Lack of medical help will result in
joint destruction and disability. Any patient suffering from rheumatoid
arthritis requires continuous treatment that is relatively very expensive.
Therefore, rheumatoid arthritis therapeutic market is highly competitive due to
increasing number of new drug approvals. Competition is fierce in the
therapeutic market among TNF-α inhibitors for patients who are refractory to
traditional disease-modifying anti-rheumatic drugs (DMARD).
Majority of the rheumatoid arthritis patients
do not respond when treated with TNF-α inhibitors. Therefore, small-molecule
DMARDs such as the Janus kinase (JAK) inhibitor and Xeljanz (tofacitinib)
replace the ineffective TNF-α inhibitors. Xeljanz is very effective because it
reduces the risk of developing cardiac diseases such as heart attack and stroke
in patients. Xeljanz is an orally administered small-molecule drug which is
used as a second-line treatment for rheumatoid arthritis patients who do not
respond to methotrexate, and as a third-line therapy for rheumatoid arthritis
patients who do not respond to biologics.
According to the study “Rheumatoid
Arthritis Therapeutics in Asia-Pacific Markets to 2023-Novel JAK and IL-6
Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars
of Blockbuster Anti-TNFs”, in Asia-Pacific region, there is a need to
improve safety in the therapeutic category. Elevated rates of infection were
observed due to frequent consequences of the immune-suppression involved in
treatments. Therefore, biological therapies are not recommended to patients who
are susceptible to any infection. There is a need to create biologics with more
convenient and less invasive drug-delivery methods because the existing
therapies for rheumatoid arthritis are administered subcutaneously or
intravenously. Such drug delivery methods in rheumatoid arthritis patients are
frequently associated with pain, rash, and allergic reactions at the injection
or infusion site, in the case of infusion, flu-like illness, fever, chills,
nausea, and headache. There is a need to develop convenient and safe drug
administration procedures for rheumatoid arthritis patients.
Advanced medical technology has witnessed
great changes in the field of diagnostic technology to strengthen the
performance of rheumatoid arthritis drug manufacturers in Asia-Pacific region.
The new products in the Asia-Pacific rheumatoid arthritis market are Sirukumab,
an antiIL6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1
inhibitors; Olokizumab, an antiIL6 humanized IgG4 mAb; and RCT18, a recombinant
human Blymphocyte stimulating factor (BLyS) receptor antibody fusion protein.
With the recently approved rheumatoid
arthritis therapies along with new therapies are sure to drive the rheumatoid
arthritis therapeutics market in Asia-Pacific. The promising pipeline companies
are Johnson & Johnson (J&J), GlaxoSmithKline (GSK)'s sirukumab, and
Galapagos's filgotinib. The leading players in rheumatoid arthritis
therapeutics market are AbbVie, Amgen, Amgen, Daiichi Sankyo, Biogen Idec,
Genentech, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck,
Pfizer, Regeneron, Sanofi, Roche and UCB.
India, Australia, China, South Korea and Japan
are the leading consumers in Asia-Pacific (APAC) rheumatoid arthritis
therapeutics market. Japan accounted for a majority share of the market,
followed by China, Australia, India and South Korea. The introduction of
biologic disease modifying antirheumatic drugs (DMARD) has helped in the growth
of the rheumatoid arthritis (RA) market in Asia-Pacific tremendously over the
last two decades. This growth is expected to continue at a moderate pace in the
next few years.
To know
more, click on the link below:
Related
Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204
No comments:
Post a Comment